NEW YORK (360Dx) – Becton Dickinson has completed its $24 billion acquisition of C.R. Bard. Starting with BD’s fiscal second quarter, it will report a new interventional segment structure, which will include most of Bard’s offerings, with the remainder reported under BD's existing medical segments. Earlier in the week, the Ministry of Commerce of the People’s Republic of China approved the acquisition, which was the final regulatory approval needed to complete the deal.
PerkinElmer closed its $1.3 billion acquisition of Euroimmun, a deal that is anticipated to expand PerkinElmer’s presence in the diagnostics space. Euroimmun, based in Lübeck, Germany, is focused on autoimmune testing, as well as infectious disease and allergy testing. PerkinElmer has said that the deal is expected to be accretive to its 2018 non-GAAP EPS by about $.28 to $.30 per share.